Acute Lymphoblastic Leukemia in Adolescents and Young Adults by Ribera, Josep-Maria & Takahashi, Satoshi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
14 
Acute Lymphoblastic Leukemia in 
Adolescents and Young Adults 
Josep-Maria Ribera  
Clinical Hematology Department 
 Institut Català d’Oncologia  
Hospital Universitari Germans Trias i Pujol  
Institut de Recerca contra la Leucemia Josep Carreras  
Universitat Autònoma de Barcelona  
Spain 
1. Introduction 
The development of effective therapy for children with acute lymphoblastic leukemia (ALL) 
is one of the greatest successes of clinical oncology, with long-term survival achieved in 
about  90% of children 1-10 years of age (Pui et al 2008, Pulte et al 2008). However, cure rates 
for adults with ALL remain relatively low, at only 40%-50% (Gokbuget et al 2009, Larson et 
al 2008). In the last two decades significant improvements in survival for older adolescent 
and adults (aged 15-59 years) with ALL have been observed, being especially evident in 
patients aged 15-19 yr. 
Age is a continuous prognostic variable in ALL with no single age at which prognosis 
deteriorates markedly. Within childhood ALL populations, older children have shown inferior 
outcomes (Pulte et al 2009, Smith et al 2010) while younger adults have shown superior 
outcomes among adult ALL patients (Moorman et al 2010, Juliusson et al 2010). The definition 
of the age range that encompasses the adolescent and young adults (AYA) patient is 
controversial, ranging from 15 to 21 yr in some studies, from 15-30 yr in others or even from 15 
to 40-45 yr in others. This chapter will focus on the results of treatment of AYA with ALL. 
2. Clinical and biologic characteristics in adolescents and young adults 
The incidence of ALL decreases with age, ranging from 9-10 cases/100,000 persons/year in 
childhood (representing 30% of all cancers) to 1-2 cases/100,000 persons/year in adults. In 
adolescents the incidence is 3 cases/100,000 persons/year and represents 6% of all cancers at 
that age (Bleyer et al 2006). 
Several clinical and biologic characteristics of ALL are age-dependent. In this sense, T-ALL 
is more frequent in AYA (25%) than in children (10-15%) or in older adults (Pullen et al 
1999). However, the most important differences lie in cytogenetic and molecular 
characteristics. For example, there is a lower frequency of hyperdiploidy >50 chromosomes 
or ETV6/RUNX1 (previously TEL/AML1) in AYAs (20%) compared to children 1 to 9 years 
of age (>30%) (Moorman et al 2010). In addition, the frequency of MLL (myeloid-lymphoid 
leukemia or mixed lineage leukemia gene, usually associated with 11q23) rearrangements in 
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non-infant ALL increases with age, being infrequent in children 1-9 yr of age and about 6% 
in adults (Moorman et al 2010). Regarding structural changes, there is a progressive increase 
in the frequency of  t(9;22)(q34;q11) or BCR-ABL rearrangements, ranging from less than 3% 
in children under 18 yr. to 6% at ages 18-25  and to 15-20% at ages 25-35 yr, and to more than 
30% over the age of 35 yr (Secker-Walker et al 1991). Finally, in recent studies, adolescents 
were more likely to have detectable minimal residual disease (MRD) during or at the end of 
remission induction (Pui et al 2011). 
In summary, with increasing age there is a progressive increase in the frequency of subsets 
of ALL patients with genetic abnormalities associated with poor prognosis and these 
changes have already become evident in AYA patients.   
As far as host factors are concerned, several features are observed in less young patients, 
being responsible for increased treatment toxicity. They include differences in the 
metabolism of chemotherapeutic agents, depleted marrow reserve and increased 
extramedullary toxicity. All these issues increase the frequency of life-threatening infections, 
organ failure, and treatment delays and dose reductions in planned chemotherapy. 
3. Which is the best treatment strategy? Pediatric-based vs. adult-based 
treatments 
3.1 Retrospective comparative studies 
A number of comparisons of the clinical outcome of adolescents enrolled in adult and 
pediatric clinical trials have resulted in interesting observations about the appropriate 
treatment strategy for prospective studies in AYA. Several retrospective reports have shown 
that adolescents (15- 20 yr.) and young adults treated by adult oncologists or hematologists 
with adult ALL protocols have poorer outcomes than similarly aged patients treated by 
pediatricians with pediatric protocols, despite having similar biologic characteristics of the 
disease (Boissel et al 2003, de Bont et al 2004, Testi et al 2004, Hallbook et al 2006, Schroeder 
et al 2006, Ramanujachar et al 2007, Lopez-Hernandez et al 2008, Stock et al 2008, Al-Khabori 
et al 2010).  
The first study in which such different outcomes were reported was performed in France 
(Boissel et al 2003).  A comparison of AYA aged 15-20 yr. treated with the pediatric-based 
protocol FRALLE-93 (n=77) with patients of the same age and comparable clinical and 
biologic characteristics of ALL who received the adult-based protocol LALA-94 (n=100) 
showed a complete remission (CR) rate of 94% vs. 83%. After a median follow-up of 3.5 yr, 
the event-free survival (EFS) probabilities were 67% vs. 41% at 5 years. Multivariate analysis 
showed an independent influence of the protocol on the outcome. The differences in the 
drugs employed and, especially in the dose-intensity, could explain the better results of the 
FRALLE-93 protocol. In this protocol the cumulated dose of prednisone was five-fold 
higher, the vinca alkaloids three-fold and the asparaginase 20-fold higher than in the LALA-
94 study. In addition, in the FRALLE-93 study the dose of prednisone in induction was 
higher and asparaginase was also given in this period, in contrast with the LALA-94 trial. 
Moreover, the time interval between CR and post-remission therapy was 2 days in FRALLE-
93 vs. 7 days in the LALA-94 study. 
The North-American Cancer and Acute Leukemia Group B (CALGB) and the Children’s 
Cancer Group (CCG) performed a retrospective comparison of presenting features, planned 
treatment, CR rate, and outcome of 321 AYA aged 16 to 20 years who were treated on 
consecutive trials in either the CCG or the CALGB from 1988 to 2001 (Stock et al 2008). Both 
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cohorts were comparable for the main clinical and biologic characteristics, although the 
median age of the patients in the CALGB studies was 19 yr. compared to 16 yr. for the CCG 
patients.  CR rates were identical (90%) for both the CALGB and CCG AYA. The CCG AYA 
had a 63% EFS and 67% overall survival (OS) probabilities at 7 years in contrast to the 
CALGB AYA, in whom the 7-year EFS was only 34% and the OS was 46%. While the 
CALGB AYA aged 16 to 17 years achieved similar outcomes to all the CCG AYA with a 7-
year EFS of 55%, the EFS for 18- to 20-year-old CALGB patients was only 29%. CALGB 
AYAs had a significant increase in CNS relapse (11%) compared to CCG AYAs (1.5%). 
Comparison of the regimens showed that the CCG AYA received earlier and more intensive 
and prolonged CNS prophylaxis and higher cumulative doses of nonmyelosuppressive 
agents (vinca alkaloid, steroids and asparaginase), as well as longer duration of maintenance 
therapy than CALGB AYAs. There were no differences in outcomes in those who reached 
maintenance therapy on time compared with those who were delayed. 
A similar Dutch study in patients aged 15-21 yr yielded similar results (de Bont et al 2004), 
with a 5-yr EFS of 69% for comparable patients treated with the more dose-intensive 
pediatric protocol  DCOG vs. 34% for those treated with adult protocols ALL-5 and ALL-18 
from the HOVON Group. Likewise, comparative retrospective studies from Italy also 
showed a poorer prognosis for patients aged 14-18 yr treated with adult-type protocols 
(Testi et al 2004). In turn, a Swedish study compared patients aged 10-40 yr treated with the 
pediatric trial NOPHO-92 (n=144) vs. a similar group of patients included in the Swedish 
Adult ALL Group (n=99) (Hallbook et al 2006). A significantly higher CR rate (99% vs. 90%) 
and EFS were observed in patients treated with the pediatric protocol, with the type of 
treatment being an independent prognostic variable on multivariate analysis. However, it is 
of note that adults aged 26-40 yr had a significantly poorer prognosis than AYA (15-25 yr.). 
Another study from Denmark yielded similar results (Schroeder et al 2006). In a 
retrospective study from the British Medical Research Council (MRC) performed only in 
adolescents (15-17 yr) included in the ALL97/revised99 (pediatric, n=61) or 
UKALLXII/E2993 (adult, n = 67) trials between 1997 and 2002 (Ramanujachar et al 2007), the 
EFS (65% vs. 49%) was higher and the rate of death in remission was lower in the former 
group of patients. In a retrospective study from the Princess Margaret Hospital from 
Toronto restricted to AYA with T-ALL 40 patients (median age 30 yr, range 17-69) were 
treated with several adult type protocols and were compared with 32 patients (median age 
32 yr, range 17-64) treated with a DFCI protocol (Al-Khabori et al 2010). Although there 
were no differences in CR attainment (93% vs. 84%), the OS and relapse-free survival (RFS) 
probabilities were significantly higher in patients treated with the DFCI trial (83% vs .56% 
and 88% vs. 23%, respectively). On multivariate analysis the treatment group (DFCI vs. non-
DFCI) was the major prognostic factor influencing both RFS and OS. Other studies from 
different countries (Lopez-Hernandez et al 2008) have shown similar results (Table 1).  
Only one population-based study from Finland showed that the outcome of AYA with ALL 
treated with pediatric or adult protocols was comparable (Usvasalo et al 2008). One hundred 
and twenty-eight patients (10-16 yr, median age 12.9 yr) were treated with the pediatric 
Nordic (NOPHO) protocols and 97 patients (17-25 yr, median age 18.9 yr) with Finnish 
Leukemia Group National protocols. All patients were centrally referred and treated in five 
academic centers. The 5-year EFS was 67% for the pediatric treatment group and 60% for the 
adult treatment group. There were no significant differences in the cumulative doses of 
corticosteroids, vincristine and asparaginase between pediatric and adult protocols, 
although pediatric protocols used a higher cumulative dose of methotrexate and lower 
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Country (reference) Protocol Age (yr) N CR (%) EFS (%) 
USA (32) CCG(P) 16-20 197 90 63 
 CALGB(A)  124 90 34 
France (12) FRALLE93(P) 15-20 77 94 67 
 LALA94 (A)  100 83 41 
Holland (13) DCOG (P) 15-18 47 98 69 
 HOVON (A)  44 91 34 
Italy (35) AIEOP (P) 14-18 150 94 80 
 GIMEMA (A)  95 89 71 
Sweden (11) NOPHO-92(P) 10-40 144 99 65 
 Adult (A)  99 90 48 
UK (25) ALL97 (P) 15-17 61 98 65 
 UKALLXII(A)  67 94 49 
Canada (1) DFCI (P) 17-64 32 84 83* 
 Adult (A) 17-69 40 93 56* 
Mexico (16) LALIN (P) 15-25 20 90 70 
 LALA (A)  20 80 40 
Finland (38) NOPHO (P) 10-25 128 96 67 
 ALL (A)  97 97 60 
N: number of patients; CR: complete remission. EFS: event-free survival.  
* Overall survival 
Table 1. Retrospective comparative studies in adolescents and young adults with acute 
lymphoblastic leukemia treated with pediatric-based (P) vs. adult-based (A) protocols. 
doses of  anthracyclines than adult protocols; epipodophyllotoxins and mitoxantrone were 
not included in the pediatric protocols. The authors attributed the similar results to the 
similarity of the pediatric and adult protocols and to the centralized care of the patients in 
five academic centers, ensuring good compliance and adherence to the protocols. Finally, 
the retrospective data from the MD Anderson Cancer Center using the Hyper-CVAD 
regimen (not including asparaginase) have also reported favorable results in 102 AYA 
(median age 19 yr), with  CR 97% and OS 65% (Thomas et al 2008). Preliminary reports from 
60 AYA patients aged 12-40 yr treated at the MD Anderson Cancer Center with modified 
augmented Berlin-Frankfurt-Münster (BFM) therapy showed very promising results (2-yr 
DFS and OS probabilities of 85% and 91%, respectively) in the subset of patients younger 
than 25 yr (Rytting et al 2010), stressing the importance of treating these patients in large 
referral centers.  
In summary, the 5- to 6-yr EFS rate for AYA treated with pediatric regimens ranges from 
65% to 70% vs. 35% to 50% for adult regimens in almost but not all retrospective 
comparative studies. However, it is of note that these studies have mainly focused on 
patients aged 15-21 years, but few have evaluated the results in young adults up to 30 years 
or more, in whom the frequency of adverse prognostic factors is progressively increasing. 
The reasons for the better results of pediatric protocols are multiple (Stock 2010). The first 
and probably the most important reason lay in the protocol itself. The dose-intensity and the 
dose-density of the key chemotherapeutic agents for ALL are clearly higher in pediatric 
protocols. This is especially relevant for drugs such as vincristine (usually capped to 2 mg in 
adult protocols), glucocorticoids, asparaginase and methotrexate. Conversely, pediatric-
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based protocols include lower doses of alkylating agents, high-dose cytarabine and 
antracyclines than adult trials. In addition CNS prophylaxis is more intense and prolonged 
in pediatric regimens than in adult trials. Most of the pediatric protocols include delayed 
intensifications and an extended maintenance chemotherapy phase, the former being 
omitted in many adult trials. The use of allogeneic stem cell transplantation (SCT) as part of 
first line therapy (associated with a transplant-related mortality [TRM] of 20%), is restricted 
to patients with very high-risk features in pediatric trials, whereas it is more widely used in 
adult trials, even in standard-risk patients in first CR.  
The second reason is the tolerability to essential drugs such as asparaginase, steroids and 
vincristine, which is poorer in AYA compared to children, being a reflection of changes in 
the metabolism of these drugs during late adolescence. The incidences of diabetes mellitus, 
pancreatitis, thrombosis and osteonecrosis are more frequent in the former group. The 
increased toxicity influences adherence to treatment, which is critical for the outcome of 
ALL patients.  
The third reason is the disparity in the practice patterns of the pediatric and adult 
hematologists/oncologists and patient compliance. Adherence to treatment is usually 
higher in pediatric than in adult-derived studies, probably due both to a highly skilled 
supportive staff, the better tolerability of pediatric protocols and a stricter control of time 
points of chemotherapy delivery in pediatric than in adult hematology units (Burke et al 
2007) However, in the U.S. and Canada most children and adolescents with ALL treated 
with pediatric protocols are managed in institutions and academic centers participating in 
national-sponsored clinical trials, whilst most AYA treated with adult protocols are 
managed throughout study groups by community-based medical oncologists. The fact that 
the most striking differences are observed in the 18 to 20-years-old group could be explained 
by the emancipation of some of these patients from parental control and support and the 
possible need to face significantly more challenges in access to health care due to insurance 
issues (Kantarjian et al 2009).  
3.2 Prospective trials 
3.2.1 Results of the treatment of adolescents in pediatric trials 
Barry et al reported the outcome of adolescents treated in the Dana-Farber Cancer Institute 
(DFCI) ALL Consortium Protocols conducted between 1991 and 2000 (Barry et al 2007). A total 
of 844 patients aged 1 to 18 years, with newly diagnosed ALL were enrolled into two 
consecutive DFCI-ALL Consortium Protocols. Outcomes were compared in three age groups: 
children aged 1 to 10 years (n = 685), young adolescents aged 10 to 15 years (n = 108), and 
older adolescents aged 15 to 18 years (n = 51). With a median follow-up of 6.5 years, the 5-year 
EFS for those aged 1 to 10 years was 85%, compared with 77% for those aged 10 to 15 years, 
and 78% for those aged 15 to 18 years. There was no difference in the rate of treatment-related 
complications between the 10- to 15-year and 15- to 18-year age groups.  
Nachman et al reported the results of the CCG1961 trial including AYA up to 21 yr 
(Nachman et al 2009). The EFS and overall survival (OS) rates were 71.5% and 77.5%, 
respectively. Rapid responder patients randomly assigned to augmented therapy had 5-year 
EFS 81.8% vs 66.8% for patients receiving standard  therapy, but 1 versus 2 interim 
maintenance and delayed intensification courses had no significant impact on EFS. WBC 
count over 50x109/L was an adverse prognostic factor. Given the excellent outcome with 
this chemotherapy there seems to be no role for the routine use of stem cell transplantation 
in first remission  
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In turn, the results of the total therapy studies XIIIA, XIIIB, XIV and XV from St Jude 
Children’s Research Hospital including 963 pediatric patients, 89 of whom were older 
adolescents (aged 15 to 18 yr.), have recently been published (Pui et al 2011). In the first 
three studies the 44 older adolescents had significantly poorer EFS and OS than the 403 
younger patients. On the contrary, in study XV (incorporing the level of MRD to guide 
treatment, with featured intensive methotrexate, vincristine, glucocorticoid and 
asparaginase and early triple intrathecal chemotherapy for higher risk ALL) the EFS of 45 
older adolescents was 86.4%, similar to 87.4% for the 453 younger children. The OS was also 
comparable (87.9% vs. 94.1%, respectively). The authors concluded that most older 
adolescents with ALL can be cured with risk-adjusted intensive chemotherapy without SCT. 
In summary, with modern approaches of treatment of ALL with pediatric-based protocols 
the unfavorable prognosis of adolescents is disappearing and hopefully, this improvement 
could be translated to young adults. 
3.2.2 Results of prospective studies in adolescent and young adults 
Some studies have evaluated or are currently evaluating the feasibility and results of the 
pediatric-based protocols administered to adults up to 30 or even up to 50 or 60 years of age 
(table 2). The Spanish PETHEMA group compared the results of the pediatric protocol 
ALL96 in adolescents (15-18yr, n=35) and young adults (18-30 yr, n=46) with standard-risk 
(SR) ALL (Ribera et al 2008). Both groups were comparable for the main clinical and biologic 
characteristics of ALL. The CR rate was 98% and after a median follow-up of 4.2 yr., 6-year 
EFS and OS were 61% and 69%, with no differences between adolescents and young adults. 
No significant differences were observed in the timing of treatment delivery, although the 
hematologic toxicity in consolidation and reinforcement cycles was higher in young adults 
than in adolescents. These results suggest that pediatric protocols can be effectively and 
safely employed in adult patients with SR ALL, at least up to the age of 30 yr.  
 
Country (reference) Protocol Age (yr) N CR (%) EFS (%) 
Spain (26) PETHEMA ALL-96 15-18 35 94 60 
  19-30 46 100 63 
France (32) GRAALL-2003 15-45 172 95 58 
USA (6) DFCI 18-50 74 82 72.5** 
Canada (34) Modified DFCI 17-71 68 85 65*** 
France (10) FRALLE2000 18-55 40 90 72*** 
* Results restricted to adolescents; **Estimated at 2 years; *** Overall survival. 
N: number of patients; CR: complete remission. EFS: event-free survival. 
Table 2. Prospective studies in adolescents and young adults with acute lymphoblastic 
leukemia treated with pediatric-based or inspired protocols 
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The French GRAALL group has reported the results of the pediatric-inspired GRAALL-2003 
study including 215 patients aged 15-60 yr (Huguet et al 2009). In this study there was an 
8.6-fold, 3.7-fold and 16-fold increase in cumulative doses of prednisone, vincristine and 
asparaginase, respectively, compared with the previous adult-based LALA-94 protocol, 
although the GRAALL-2003 trial retained some adult options, such as allogeneic SCT for 
patients with high-risk ALL. The CR rate was 93.5% and at 42 months the EFS and overall 
survival (OS) rates were 55% and 60%, respectively. The CR rate, EFS and OS compared 
favorably with the previous LALA-94 experience.  It is of note, however, that in patients 
over 45 yr there was a higher cumulative incidence of chemotherapy-related deaths (23% vs. 
5%) and deaths in first CR (22% vs. 5%), although the incidence of relapse remained stable 
(30 vs. 32%). The results of this study suggest that pediatric-inspired therapy is feasible in 
young adults with ALL at least until the age of 45 yr, in whom the outcome clearly 
improves. 
Based on the promising results obtained in adolescents with ALL, the DFCI Combined 
Adult/Pediatric ALL Consortium has applied a true pediatric protocol to adults aged 18-50 
yr (DeAngelo et al 2006). Specifically, the investigators used an extended course of 
asparaginase for 30 weeks. The preliminary results in 94 patients, with a median age of 28 yr 
have shown a CR in 79 patients (84%). With a median follow-up of 45 months, the estimated 
DFS rate was 66% and the OS rate was 68%. This study proved that extended asparaginase 
treatment was feasible in adults and the drug-related toxicity was manageable, although the 
incidence of pancreatitis (13%) and thrombosis/embolism (19%) was a matter of concern. In 
turn, the Princess Margaret Hospital used a modified Dana Farber Cancer Institute pediatric 
protocol in 68 adult patients (17 to 71 yr), with a CR rate of 85% and 3-yr OS and DFS of 65% 
and 77%, respectively (Storring et al 2009). The University of South California group 
(Srivastava et al 2008) used an augmented BFM pediatric regimen with eight doses of 
pegylated asparaginase to treat adults with ALL aged 19-57 yr (median 33), with a 3-yr 
projected EFS of 65%. Toxicity attributable to asparaginase was frequent but manageable. 
However, older patients had significantly less tolerance to asparaginase, vincristine and 
steroids compared to children or adolescents. In the FRALLE group from France 28 
Philadelphia chromosome-negative adult ALL patients 16 to 57 years of age were treated in 
the FRALLE 2000 protocol consisting of a prednisone pre-phase and a four-drug induction 
including asparaginase, consolidation, delayed intensification and maintenance 
chemotherapy. The 4-yr DFS was 90% vs. 47% seen in matched historical controls (Haiat et 
al 2011). 
The largest prospective phase II trial to evaluate the feasibility of the use of a true pediatric 
regimen in AYA is currently ongoing in the US (C-10403 trial) (available at 
www.clinicaltrials.gov. NCT00558519) AYAs from 16 to 39 yr are treated by adult 
oncologists/hematologists with one treatment arm of the current AALL0232 trial from the 
pediatric COG group. More than half of the 300 planned patients have been currently 
enrolled. This study will prospectively analyze the genetic characteristics, MRD, treatment 
adherence, tolerability and psycho-social and socio-economic conditions that likely 
influence treatment outcomes.  
The results from these prospective studies demonstrate the feasibility and tolerability of 
pediatric-based regimens in AYA with SR ALL, at least until 30-50 yr. All these trials have 
the increased cumulative dosages of the most important drugs for ALL therapy, the cautious 
observance of dose-intensity and the reduction of the delays between the different phases of 
the therapy in common. If these results can be confirmed with a longer follow-up, they will 
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have an impact on the clinical management of AYA patients in the future. Finally, few 
specific data are available on long-term complications of successful treatment of AYA (see 
www.survivorshipguidelines.org by the COG group) and a comprehensive approach to the 
follow-up for this significant group of patients with ALL is lacking. The next generation of 
studies, incorporating biological, pharmacological and psychosocial issues will further 
improve the cure rate and quality of life of these patients.  
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